Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 11.17
(0.63%)
CNY 11.17
(0.63%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.88 Billion CNY | -25.0% |
| 2022 | 2.48 Billion CNY | 10.55% |
| 2021 | 2.25 Billion CNY | -2.19% |
| 2020 | 2.3 Billion CNY | -26.53% |
| 2019 | 3.13 Billion CNY | -0.05% |
| 2018 | 3.13 Billion CNY | 21.32% |
| 2017 | 2.58 Billion CNY | 143.99% |
| 2016 | 1.05 Billion CNY | 55.04% |
| 2015 | 683.14 Million CNY | 14.27% |
| 2014 | 597.84 Million CNY | 38.37% |
| 2013 | 432.06 Million CNY | 31.83% |
| 2012 | 327.74 Million CNY | 70.24% |
| 2011 | 192.52 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 481.51 Million CNY | 16.88% |
| 2024 Q3 | 457.58 Million CNY | -2.14% |
| 2024 Q2 | 467.61 Million CNY | -2.89% |
| 2023 Q4 | 411.97 Million CNY | -16.58% |
| 2023 FY | 1.86 Billion CNY | -25.0% |
| 2023 Q1 | 490.89 Million CNY | -16.5% |
| 2023 Q3 | 493.82 Million CNY | 1.63% |
| 2023 Q2 | 485.91 Million CNY | -1.01% |
| 2022 FY | 2.48 Billion CNY | 10.55% |
| 2022 Q2 | 713.24 Million CNY | 23.52% |
| 2022 Q4 | 587.86 Million CNY | -3.71% |
| 2022 Q1 | 577.44 Million CNY | 8.9% |
| 2022 Q3 | 610.52 Million CNY | -14.4% |
| 2021 Q3 | 599.92 Million CNY | 1.66% |
| 2021 FY | 2.25 Billion CNY | -2.19% |
| 2021 Q1 | 531.22 Million CNY | -3.84% |
| 2021 Q2 | 590.12 Million CNY | 11.09% |
| 2021 Q4 | 530.25 Million CNY | -11.61% |
| 2020 Q4 | 552.46 Million CNY | -12.38% |
| 2020 Q3 | 630.5 Million CNY | -7.01% |
| 2020 FY | 2.3 Billion CNY | -26.53% |
| 2020 Q1 | 440.99 Million CNY | -43.39% |
| 2020 Q2 | 678.05 Million CNY | 53.76% |
| 2019 Q3 | 828.37 Million CNY | -0.69% |
| 2019 FY | 3.13 Billion CNY | -0.05% |
| 2019 Q4 | 779.05 Million CNY | -5.95% |
| 2019 Q2 | 834.13 Million CNY | 20.56% |
| 2019 Q1 | 691.87 Million CNY | -12.06% |
| 2018 Q1 | 460.74 Million CNY | -66.98% |
| 2018 Q4 | 786.76 Million CNY | -11.65% |
| 2018 Q2 | 997.1 Million CNY | 116.41% |
| 2018 Q3 | 890.51 Million CNY | -10.69% |
| 2018 FY | 3.13 Billion CNY | 21.32% |
| 2017 Q3 | 465.69 Million CNY | 14.82% |
| 2017 FY | 2.58 Billion CNY | 143.99% |
| 2017 Q1 | 317.35 Million CNY | -18.16% |
| 2017 Q2 | 405.57 Million CNY | 27.8% |
| 2017 Q4 | 1.39 Billion CNY | 199.67% |
| 2016 Q3 | 286.9 Million CNY | 34.98% |
| 2016 FY | 1.05 Billion CNY | 55.04% |
| 2016 Q2 | 212.55 Million CNY | 23.65% |
| 2016 Q1 | 171.9 Million CNY | -10.35% |
| 2016 Q4 | 387.77 Million CNY | 35.16% |
| 2015 Q1 | 146.75 Million CNY | -7.33% |
| 2015 Q4 | 191.74 Million CNY | 6.91% |
| 2015 Q3 | 179.35 Million CNY | 8.52% |
| 2015 Q2 | 165.28 Million CNY | 12.62% |
| 2015 FY | 683.14 Million CNY | 14.27% |
| 2014 FY | 597.84 Million CNY | 38.37% |
| 2014 Q3 | 177.88 Million CNY | 19.23% |
| 2014 Q4 | 158.37 Million CNY | -10.97% |
| 2014 Q1 | 112.4 Million CNY | 0.0% |
| 2014 Q2 | 149.19 Million CNY | 32.73% |
| 2013 FY | 432.06 Million CNY | 31.83% |
| 2012 FY | 327.74 Million CNY | 70.24% |
| 2011 FY | 192.52 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 13.4 Billion CNY | 85.935% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion CNY | 74.46% |
| Dirui Industrial Co.,Ltd. | 1.36 Billion CNY | -38.329% |
| Beijing Strong Biotechnologies, Inc. | 1.74 Billion CNY | -8.282% |
| Maccura Biotechnology Co.Ltd | 2.89 Billion CNY | 34.875% |
| Guangzhou Wondfo Biotech Co.,Ltd | 2.76 Billion CNY | 31.793% |
| Guangdong Hybribio Biotech Co.,Ltd. | 1.1 Billion CNY | -70.751% |
| BGI Genomics Co., Ltd. | 4.34 Billion CNY | 56.643% |
| Amoy Diagnostics Co., Ltd. | 1.03 Billion CNY | -81.537% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1.67 Billion CNY | -12.632% |